For secondary outcomes, GLP-1 RAs significantly reduced the risks of systolic heart failure (SHF, HR = 0.60) and stroke (HR = 0.75) compared to SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and Stroke.